Stockscreener 앱 받기
20.05
3.79%
-0.79
시장 영업 전:
20.05
전일 마감가:
$20.84
열려 있는:
$20.9
하루 거래량:
344.58K
Relative Volume:
0.94
시가총액:
$722.17M
수익:
$10.00M
순이익/손실:
$-75.99M
주가수익비율:
-8.3986
EPS:
-2.3873
순현금흐름:
$-80.36M
1주 성능:
-2.15%
1개월 성능:
-12.52%
6개월 성능:
+26.42%
1년 성능:
+0.00%
1일 변동 폭
$19.98
$20.92
1주일 범위
$19.77
$21.61
52주 변동 폭
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
명칭
Evommune Inc
전화
(650) 223-7745
주소
1891 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
20.05 | 750.62M | 10.00M | -75.99M | -80.36M | -2.3873 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-07 | 재개 | Oppenheimer | Outperform |
| 2026-01-22 | 개시 | Oppenheimer | Outperform |
| 2026-01-08 | 개시 | Raymond James | Strong Buy |
| 2026-01-06 | 개시 | H.C. Wainwright | Buy |
| 2025-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 개시 | Evercore ISI | Outperform |
| 2025-12-01 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 개시 | Morgan Stanley | Overweight |
| 2025-12-01 | 개시 | William Blair | Outperform |
모두보기
Evommune Inc 주식(EVMN)의 최신 뉴스
Evommune Inc. (EVMN) Declines 4.16% as Stock Tests Key Support at $18.84Double EMA - newsline.com
Evommune Inc. (EVMN) Slips 4.16% as Biotech Sentiment SoftensMomentum Stock Picks - newsline.com
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
EVMN SEC FilingsEVOMMUNE INC 10-K, 10-Q, 8-K Forms - Stock Titan
Evommune director Cohen sells $123,093 in stock By Investing.com - Investing.com India
Insider Sell: Luis Pena Sells Shares of Evommune Inc (EVMN) - GuruFocus
Evommune CSO Patel sells $379k, acquires $51k in stock - Investing.com UK
Evommune president & CEO Luis C. Pena sells $381,736 in stock - Investing.com Nigeria
Evommune president & CEO Luis C. Pena sells $381,736 in stock By Investing.com - Investing.com South Africa
Evommune director Cohen sells $123,093 in stock - Investing.com
Evommune CSO Patel sells $379k, acquires $51k in stock By Investing.com - Investing.com Australia
Evommune (EVMN) grants director 15,673 stock options at $19.82 - Stock Titan
Evommune (EVMN) CEO Luis C. Pena sells 16,787 shares under 10b5-1 plan - Stock Titan
Evommune (EVMN) director sells 6,056 shares and receives option grant - Stock Titan
Broker files proposed sale of EVMN (NYSE: EVMN) — 9,258 shares listed - Stock Titan
Evommune (EVMN) elects directors and ratifies BDO as auditor - Stock Titan
Evommune (EVMN) investors back board nominees and ratify BDO USA as 2026 auditor - Stock Titan
EVMN: Directors and auditor were approved, with no shareholder questions and quorum established - TradingView
Evommune CFO Kyle Carver sells $415,117 of EVMN stock By Investing.com - Investing.com UK
Evommune chief business & legal officer sells $324,711 in stock By Investing.com - Investing.com Australia
Evommune CFO Kyle Carver sells $415,117 of EVMN stock - Investing.com
Evommune chief business & legal officer sells $324,711 in stock - Investing.com
Evommune (EVMN) officer exercises options and sells 14,223 shares under 10b5-1 plan - Stock Titan
Evommune (EVMN) CFO sells 18,175 shares under 10b5-1 plan - Stock Titan
Morgan Stanley Smith Barney (EVMN) files Form 144 listing 24,225 shares - Stock Titan
15,000-Share Rule 144 Notice for EVMN (EVMN) by Morgan Stanley - Stock Titan
Number of shareholders of Evommune, Inc. – NYSE:EVMN - TradingView
[144] Evommune, Inc. SEC Filing - Stock Titan
EVMN (NYSE: EVMN) broker files to sell 22,500 shares on 05/28/2026 - Stock Titan
Evommune Inc. (EVMN) Slides 1.46% Amid Cautious Sector Tone; Support at $21.85 in FocusDonchian Channel - newsline.com
H.C. Wainwright Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Evommune Inc. (EVMN) Q1 2026 Earnings: EPS Beats Estimates as Pre-Revenue Biotech Focuses on Pipeline ProgressProduct Revenue Analysis - The Legal Advocate
H.C. Wainwright reiterates Evommune stock rating on trial progress By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Evommune stock rating on trial progress - Investing.com
Number of shareholders of Evommune, Inc. – BX:EVMN - TradingView
Evommune (EVMN) Insider Trading Activity 2026 - MarketBeat
Evommune (EVMN) Institutional Ownership 2026 - MarketBeat
Oppenheimer Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Evommune Inc (EVMN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):